A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
A phase 2 trial of RO7198457 intravenous (IV) in colorectal cancer, run by BioNTech SE, active and no longer recruiting.
Overview
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer is a phase 2 interventional study registered as NCT04486378 by BioNTech SE, with 327 participants enrolled, started 2021-03-08 and due to reach its primary completion in 2026-11. Interventions recorded: RO7198457 intravenous (IV).
Similar pages
not linked directly; found by shared links- TrialA Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Shares Flatiron Health (Roche), BioNTech and the tag pipeline.
- TrialA Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Shares Flatiron Health (Roche) and the tag pipeline.
- TrialSafety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
Shares BioNTech and the tag pipeline.
- TrialA Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Shares BioNTech and the tag pipeline.
- TrialEarly-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors
Shares BioNTech and the tag pipeline.
- TrialA Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Shares Flatiron Health (Roche) and the tag pipeline.
- TrialA Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
Shares Flatiron Health (Roche) and the tag pipeline.
- TrialA Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
Shares BioNTech and the tag pipeline.